Doctors Debate: Should Maintenance Therapy Be Included in the Treatment of Acute Myeloid Leukemia?October 20th 2021
Despite the success of implementing maintenance therapy in other leukemias, the key challenge with administering maintenance therapy in acute myeloid leukemia has been identifying an effective drug.
Testing Strategies for Identifying Eosinophilia in Patients With Myeloid/Lymphoid NeoplasmsOctober 16th 2021
In an interview with Targeted Oncology, Annette S. Kim, MD, PhD, discussed the updates to the NCCN guidelines on myeloid/lymphoid neoplasms with eosinophilia, along with how to bring new pathology strategies for these disease into clinical practice.
FDA Approval Sought for Beti-Cel to Treat B-Thalassemia Requiring TransfusionsSeptember 22nd 2021
A biologics license application has been submitted to the FDA for betibeglogene autoemcel gene therapy for the treatment of adult, adolescent, and pediatric patients with B-thalassemia who require regular blood cell transfusions.
Rituximab Plus Bendamustine Outperforms DRC and BDR Regimens in Waldenström MacroglobulinemiaSeptember 10th 2021
Rituximab with bendamustine lead to superior outcomes compared with than 2 other popular triplet therapies in patients with treatment-naïve Waldenström macroglobulinemia.
New Options in the Treatment of Patients with Low-Risk Myelodysplastic Syndrome Need to Be Further StudiedSeptember 8th 2021
For patients with low-risk myelodysplastic syndrome, standardized treatment options are not readily available and dependent on the patient’s specific conditions.
FDA Grants Priority Review to Abatacept to Prevent Moderate to Severe Acute GVHDAugust 23rd 2021
The FDA has accepted the supplemental biologics license application for abatacept and granted it priority review for the prevention of moderate to severe acute graft versus host disease in patients 6 years of age and older receiving unrelated donor hematopoietic stem cell transplantation.
Later-Generation Cellular Therapies Look Promising in Hematologic MalignanciesAugust 14th 2021
As more chimeric antigen receptors undergo clinical development for the treatment of hematologic malignancies, their approval for use in a wider array of malignancies is inevitable.
FDA Grants Fast Track Designation to Novel Asparaginase Therapy for ALL SubsetJuly 30th 2021
Fast track designation has been granted by the FDA to eryaspase for the treatment of patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.